Biotest AG: Biotest AG signs strategically significant agreement to market human albumin in China
Biotest AG / Key word(s): Contract / Biotest AG signs strategically significant agreement to market human albumin in China - Access to fast growing, high-price Chinese albumin market - Revenue of EUR 20 to EUR 30 million expected in medium term - Strong sales and distribution partner Wanbang Biopharma, a Fosun Pharma Group company, as guarantee for success
In view of the growing importance of the Chinese market, Biotest has successfully realised the extension of the marketing authorization for human albumin. With regard to rising production capacities, we have looked for a strong sales and distribution partner with whom we can successfully implement our ambitious growth objectives. In 2011, 180 tonnes of human albumin were sold in China, more than 40% of which were imported. The Chinese pharmaceutical market has reported an annual growth in excess of 20% over the last five years. It is expected that China will be the world's second-largest pharmaceuticals market* by 2014, with sales of around EUR 85 billion. Wanbang Biopharma is part of the Fosun Pharmaceuticals Group, and is thus one of China's largest pharmaceutical companies. Wanbang Biopharma operates subsidiaries in 28 provinces and employs more than 1,200 marketing and sales staff. With this newly-launched cooperation venture Biotest has secured a position on the Chinese albumin market. Should the Chinese market for plasma products open further, its significance will increase considerably. About Fosun Pharma Fosun Pharma is one of the largest Chinese pharmaceutical companies. With a broad pharmaceutical product portfolio, fast growing therapeutic areas such as infectious, liver and mass diseases such as diabetes are served. A strategic partnership with Sinopharma and the most important pharmacists' retail chains ensure an extensive distribution network. * IMS Report, Datamonitor, MOH year book Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so. About Biotest Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de Securities' ID No., ISIN ordinary shares: 522720, DE0005227201 End of Corporate News 11.12.2012 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.medientreff.de and www.dgap.de |
| Language: | English | |
| Company: | Biotest AG | |
| Landsteinerstraße 5 | ||
| 63303 Dreieich | ||
| Germany | ||
| Phone: | 0 61 03 - 8 01-0 | |
| Fax: | 0 61 03 - 8 01-150 | |
| E-mail: | investor_relations@biotest.de | |
| Internet: | http://www.biotest.de | |
| ISIN: | DE0005227235, DE0005227201 | |
| WKN: | 522723, 522720 | |
| Indices: | SDAX | |
| Listed: | Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, Stuttgart | |
| End of News | DGAP News-Service |
| 196623 11.12.2012 |